Stock Detail
PDL BIOPHARMA INC
Biotechnology
PDLI @ Yahoo Finance | PDLI Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $6.03 | $6.12 | $-0.08 | -1.31% | 0.60 | $6.11 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $6.07 | $6.02 | 805,403 | 843.2M | 2.03M | 8.06 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 6.16 | 6.10 | 6.06 | 6.00 | 5.96 |
Stock Profile
PDL BioPharma, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for treatment of inflammation and autoimmune diseases, acute cardiac conditions, and cancer. It markets and distributes various biopharmaceutical products, including Cardene I.V. for the short-term treatment of hypertension; Retavase, a fibrinolytic agent for the management of acute myocardial infarction or heart attack in adults for the improvement of ventricular function; and IV Busulfex that is used as a conditioning agent in blood or marrow transplantation in chronic myelogenous leukemia. The company also develops various other products, such as Daclizumab for the treatment of asthma and multiple Sclerosis; Ularitide to treat decompensated congestive heart failure; Terlipressin for the treatment of Type 1 hepatorenal syndrome; HuZAF to treat crohn's disease; Nuvion for the treatment of severe steroid-refractory ulcerative colitis; and M200 to treat solid tumors. PDL BioPharma markets its biopharmaceutical products in the United States and Canada through its hospital sales force. The company was founded by Laurence Jay Korn in 1986. It was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in June 2005. PDL BioPharma is headquartered in Fremont, California.